VEXAS Syndrome for the laboratory physician: a case report - Takeaways - MDSpire

VEXAS Syndrome for the laboratory physician: a case report

  • By

  • Chaoying Chen

  • Miaomiao Chen

  • Tieqiao Chen

  • Yong Chen

  • Lingzhi Liu

  • Yixi Zhu

  • Xiaoming Yi

  • Shuguang He

  • May 6, 2026

Share

  • 1

    VEXAS syndrome is a recently identified systemic condition linked to somatic mutations in the UBA1 gene, causing autoinflammatory features.

  • 2

    The diagnosis of VEXAS syndrome involves recognizing clinical manifestations such as fever, rash, arthritis, and specific laboratory findings.

  • 3

    Current treatment strategies for VEXAS syndrome include high doses of corticosteroids and allogeneic hematopoietic stem cell transplantation.

  • 4

    Patients with VEXAS syndrome have a higher risk of developing malignant neoplasms compared to those with other autoinflammatory diseases.

  • 5

    Early identification and diagnosis of VEXAS syndrome are crucial for improving patient outcomes and require collaboration among healthcare professionals.

Original Source(s)

VEXAS Syndrome for the laboratory physician: a case report

  • by Chaoying Chen, Miaomiao Chen, Tieqiao Chen, Yong Chen, Lingzhi Liu, Yixi Zhu, Xiaoming Yi, Shuguang He

  • May 6, 2026

Related Content

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to explore advances in scaling cell and gene therapies

  • May 6, 2026

  • 1 min
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).